Advertisement

Topics

Latest "Targeted Oncology" News Stories

08:55 EST 17th February 2019 | BioPortfolio

Here are the most relevant search results for "Targeted Oncology" found in our extensive news archives from over 250 global news sources.

More Information about Targeted Oncology on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Targeted Oncology for you to read. Along with our medical data and news we also list Targeted Oncology Clinical Trials, which are updated daily. BioPortfolio also has a large database of Targeted Oncology Companies for you to search.

Showing "Targeted Oncology" News Articles 1–25 of 6,700+

Relevant

Gilead Sciences and Tango Therapeutics Collaborate to Develop Targeted Oncology Therapies

NewsThe collaboration aim to discover, develop, and commercialize a pipeline of innovative targeted immuno-oncology treatments.


Sierra Oncology (SRRA) Presents On Targeted Hematology & Oncology Therapeutics - Slideshow

Gilead, Tango to partner on targeted immuno-oncology therapies

Under the multi-year collaboration, Tango will perform target discovery and validation and Gilead will have options to worldwide rights on up to five targets emerging from Tango’s proprietary The post Gilead, Tango to partner on targeted immuno-oncology therapies appeared first on Pharma Business review.


Lilly to acquire Loxo Oncology for $8bn

Loxo Oncology is engaged in the development and commercialization of highly selective drug candidates for patients with genomically defined cancers. The company is developing targeted drugs that are The post Lilly to acquire Loxo Oncology for $8bn appeared first on Pharmaceutical Business review.

TAT International Congress 2019: The home of phase I oncology

(European Society for Medical Oncology) The European Society for Medical Oncology, the leading professional organization for medical oncology, is pleased to announce the TAT (Targeted Anticancer Therapies) International Congress 2019, the premier forum for discussion of early phase drug development and translational research.

Innovations in Digital and Targeted Treatment Platforms, 2018 Report – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Innovations in Digital and Targeted Treatment Platforms” report has been added to ResearchAndMarkets.com’s offering. This Genetic Technology TOE depicts new life sciences trends across digital targeted therapeutic platforms. Human genetics, antibody therapies, digital oncology platforms, among others, are … Continue reading → Ce...

Targeted Therapies in Oncology Welcomes Dr. Robert Ferris as Co-Physician Editor-In-Chief

Dr. Ferris will help Targeted Therapies in Oncology increase its frequency to two issues a month beginning in December. Targeted Therapies in Oncology, an oncology publication that provides oncology professionals with cutting-edge research, data, and treatment strategies surrounding molecular and immune system targets, has appointed Robert L. Ferris, M...

CTLA4 targeted therapy plus PD-1 targeted therapy could benefit women with ovarian cancer

(NRG Oncology) An analysis of the NRG Oncology clinical trial NRG-GY003 suggests that adding ipilimumab, a monoclonal antibody that targets the protein receptor CTLA-4, to a regimen with the checkpoint inhibitor nivolumab could improve the proportion with tumor response and progression-free survival hazard rates for women with recurrent epithelial ovarian cancer. These results were presented as a ...

IGF Oncology in Phase 1b/2a for its blood cancer treatment at the Mayo Clinic

IGF Oncology CEO Hugh McTavish sat down with Proactive Investors at the 11th Annual Biotech Showcase in San Francisco. IGF Oncology is a biotech company developing targeted anti-cancer drugs. Its lead drug, IGF-MTX, targets blood cancer, and is currently in clinical trials at the Mayo Clinic.

Gilead and Tango Therapeutics Announce Strategic Collaboration to Develop Next-Generation Targeted Immuno-Oncology Therapies

FOSTER CITY, Calif. & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Gilead Sciences, Inc. (Nasdaq: GILD) and Tango Therapeutics, Inc., a company focused on the discovery and development of novel cancer therapies, today announced a global strategic collaboration to discover, develop and commercialize a pipeline of innovative targeted immuno-oncology treatments for patients with cancer. Under the...

New ESMO tumor DNA scale helps match patients with cancer to optimal targeted medicines

(European Society for Medical Oncology) A new scale for tumour DNA mutations which will simplify and standardise choices for targeted cancer treatment has been agreed by leading cancer specialists in Europe and North America. The scale, called ESCAT (ESMO Scale for Clinical Actionability of molecular Targets), is published this week in the Annals of Oncology. It aims to optimise patient care by ma...

Sierra Oncology Acquires Gilead’s Momelotinib, an Investigational JAK 1/2 and AACVR1 Inhibitor for Myelofibrosis

VANCOUVER, Aug. 22, 2018 /PRNewswire/ – Sierra Oncology, Inc. (Nasdaq : SRRA ), a clinical stage drug development company focused on advancing targeted therapeutics for the treatment of patients with significant unmet needs in hematology and oncology, today announced it has acquired the drug candidate momelotinib from Gilead Sciences. Momelotinib has been investigated in two …

New Scale Grades Mutations, Optimizing Targeted Cancer Therapy

A new scale for tumor DNA mutations has been developed by the European Society for Medical Oncology, which will simplify and standardize choices for targeted cancer treatment. Medscape Medical News

Gilead pens $1.75bn deal with start-up Tango Therapeutics

Oncology start-up Tango Therapeutics Inc. signed its first major alliance, agreeing to discover and develop targeted immuno-o...

Precision Medicine: Getting Oncology Drug Development Right

With the U.S. Food and Drug Administration approving an increasing number of targeted therapies and hundreds more in late-stage oncology pipelines close behind, pharmaceutical companies are racing to bring cancer patients drugs tailored to the molecular profile of their tumors, otherwise known as precision medicine. Hitting the right target in precision medicine, however, is fraught […] The ...

Recent IPO Gritstone Oncology: Neoantigen Targeted Personalized T Cell Therapy In Cancers

Addition of CTLA4 targeted therapy to PD-1 targeted therapy may benefit patients with ovarian cancer

An analysis of the NRG Oncology clinical trial NRG-GY003 suggests that adding ipilimumab, a monoclonal antibody that targets the protein receptor CTLA-4, to a regimen with the checkpoint inhibitor nivolumab could improve the proportion with tumor response and progression-free survival hazard rates for women with recurrent epithelial ovarian cancer.

Crescendo Biologics announces early licensing by Takeda of first oncology-targeted Humabody®

CAMBRIDGE, England–(BUSINESS WIRE)–Crescendo Biologics Ltd (Crescendo), the drug developer of novel, targeted T-cell enhancing therapeutics, today announces that Takeda Pharmaceutical Company Limited (Takeda), has exercised an option under its existing, multi-target collaboration and license agreement. Takeda has taken an exclusive … Continue reading →

Thermo Fisher Launches Ion AmpliSeq HD Technology

New product is for targeted next-gen sequencing (NGS) oncology and genetic research applications

Gilead enters deal with Tango Therapeutics to develop targeted immuno-oncology drugs https://www.firstwordpharma.com/node/1601142  $GILD

Gilead enters deal with Tango Therapeutics to develop targeted immuno-oncology drugs https://www.firstwordpharma.com/node/1601142  $GILD

LR Stocks outperforming market: $BPMC ($105 PT): Leader in targeted oncology, expect competitive threats to subside in GIST &SM, and still a significant player in RET.

LR Stocks outperforming market: $BPMC ($105 PT): Leader in targeted oncology, expect competitive threats to subside in GIST &SM, and still a significant player in RET.

Molecular Templates and Takeda Enter Agreement for the Joint Development of a Protein-Based Oncology Therapy

AUSTIN, Texas, Sept. 19, 2018 (GLOBE NEWSWIRE) — Molecular Templates, Inc. (Nasdaq:MTEM) today announced an agreement with Takeda Pharmaceutical Company Limited (Takeda) for the joint development of CD38-targeted engineered toxin bodies (ETBs) for the treatment of patients with diseases such as multiple myeloma. The lead development candidate is a CD38-targeted ETB that resulted from a pre...

Is Upfront Combo Therapy Better Than the Sum of Its Parts?

Lung cancer studies presented at ASCO 2018 demonstrate the enduring value of chemotherapy, even in the age of targeted and immunotherapies, argues Jack West, MD. Medscape Oncology

Almac Discovery, Elasmogen and Innovate UK collaborate

The £2 million collaborative project will aim to build a versatile platform to facilitate the discovery and development of targeted oncology therapeutics

Targeted integration in human cells through single crossover mediated by ZFN or CRISPR/Cas9

Targeted DNA integration is widely used in basic research and commercial applications because it eliminates positional effects on transgene expression. Targeted integration in mammalian cells is generally achi...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks